US private equity house Genstar Capital is reportedly hoping to reach a $5bn price tag for pharmaceuticals and regulatory consulting business Advarra through a potential sale.
The firm picked up Advarra from fellow buyout investor Linden Capital Partners in 2019, in a deal believed to value the business at about $1.3bn.
Genstar raced to an $11.7bn close for its tenth fund last year – a huge increase on the already weighty $5.5bn Fund IX it closed in 2019.
Recent deals from the firm have included buying Arrowhead Engineered Products, a global provider of replacement parts for motorised vehicles and equipment, from The Riverside Company and Investcorp.
